ASX RELEASEMEDICAL MONITORS LIMITED (MDM) ABN 68 009 161...

ASX RELEASE
MEDICAL MONITORS LIMITED (MDM) ABN 68 009 161 522
Medical Monitors Limited
Suite 407 Westfield Eastgardens
Eastgardens NSW 2036
Tel (02) 9344 8100 Fax (02) 9344 8200
Web site: www.medmon.com.au
5th October 2004
USA and UK Business Venture to List on AIM
The Directors of Medical Monitors Limited (ASX: MDM) have granted a new licensing
and distribution agreement to Primedical International Plc. (Primedical), a newly
established UK-based investment group. This transaction will replace the recent
‘documentation pending’ announcement with Gallery Investments, Inc., of the USA.
Primedical will have the exclusive license and distribution rights for the USA, the UK and
European Community (EU) countries, subject to its completion of a further capital raising,
for Medical Monitors’ products and services. Primedical will have the financial support of
several strategic partners, including a London- based private investment group. Medical
Monitors will obtain a major shareholding in Primedical, as well as benefit from an agreed
profit margin manufacturing contract and royalty revenue.
Primedical intends to access the London Stock Exchange’s Alternative Investment
Market (AIM) to provide for further capitalisation, as well as facilitate ‘pre-AIM’ funding of
a minimum of £1,000,000 before December 31, 2004. Primedical has engaged one of
the UK’s top five biotechnology and corporate brokers in London, who has provided an
independent valuation of the business prior to undertaking the AIM listing .
Medical Monitors shareholders will be offered a priority placement on the future AIM
listing as part of the exclusive relationship with Primedical.
Currently, the Directors are in final negotiation for funding of up to $1.0 million, for the
company’s Australian operation, for the required manufacturing and technology support
of the new venture.
About Medical Monitors
Medical Monitors’ technology and service model remain superior to the current market
offerings in transtelephonic (telephone transfer) cardiac monitoring , and the company will
be well placed to take a substantial share of the lucrative international markets.
Medical Monitors’ unique transtelephonic (telephone transfer) technologies, which allow
doctors to remotely monitor the cardiovascular health of their patients, have already been
granted United States Food and Drug Administration (FDA) notification to enable
marketing and sales in the USA.
For further information, please contact Dr Allan Shell on (02) 9344 8100.

Regards

Commy